Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (KYTX): 3 pipeline candidates · 1 upcoming catalyst · ~16 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.4 months
D/E 0.31 · 0% dilution
Lead: Phase 2/Phase 3
3 candidates
1 upcoming, next in ~806d
N/A
A transparent, data-derived signal for Kyverna Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$495.5M
Cash
$32.2M
Quarterly Burn
$41.6M
Runway
16.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| kyv-101 | Phase 2/Phase 3 |
| kyv-101 anti-cd19 car-t cell therapy | Phase 2/Phase 3 |
| standard lymphodepletion regimen | Phase 2/Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
108
Total value held
$222.1M
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 4,126,119 | $35.6M |
| vanguard capital management llc | 3,566,684 | $30.8M |
| deerfield management company, l.p. | 2,000,000 | $17.3M |
| woodline partners lp | 1,690,650 | $14.6M |
| balyasny asset management l.p. | 1,125,321 | $9.7M |
| millennium management llc | 1,005,508 | $8.7M |
| morgan stanley | 977,289 | $8.4M |
| blackrock, inc. | 877,078 | $7.6M |
| d. e. shaw & co., inc. | 721,581 | $6.2M |
| propel bio management, llc | 644,421 | $5.6M |
Showing top 10 of 108 institutional holders of Kyverna Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kyverna Therapeutics, Inc.'s pipeline?
Kyverna Therapeutics, Inc. (KYTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kyverna Therapeutics, Inc.'s lead drug candidate?
Kyverna Therapeutics, Inc.'s most advanced tracked candidate is kyv-101 (Phase 2/Phase 3) for Refractory Lupus Nephritis; Myasthenia Gravis; Systemic Sclerosis.
What is Kyverna Therapeutics, Inc.'s next catalyst?
Kyverna Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous" — expected September 1, 2028.
What is Kyverna Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kyverna Therapeutics, Inc. has approximately 16.4 months of cash runway.
What is Kyverna Therapeutics, Inc.'s market capitalization?
Kyverna Therapeutics, Inc.'s market capitalization is approximately $495.5M.
Get the full picture on Kyverna Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.